Sleep disturbances in progressive supranuclear palsy syndrome (PSPS) and corticobasal syndrome (CBS)

Alster, Piotr; Madetko, Natalia; Migda, Anna; Migda, Bartosz; Kutyłowski, Michał; Królicki, Leszek; Friedman, Andrzej

doi:10.5603/pjnns.a2023.0019

Cited by 6 publications

(3 citation statements)

References 61 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The lack of influence of sleep disorders in PSP patients on the occurrence of ICDs may be due to a different type of sleep disorders and other mechanisms of their development compared to PD [69,70]. In PSP, which is a tauopathy, the most common sleep disorders are deviated sleep architecture and insomnia, and they are more severe than those occurring in PD, which is mainly associated with more severe neurodegenerative changes in the brain stem and greater severity of orexin neurotransmission disorders than PSP [71][72][73]. In PD, however, REM sleep disorders (RBD), which are typical for synucleinopathies, are more than twice as common, which some researchers associate with a higher incidence of ICDs [74,75].…”

Section: Discussionmentioning

confidence: 99%

Impulse Control Disorders in Parkinson’s Disease and Atypical Parkinsonian Syndromes—Is There a Difference?

Toś,

Grażyńska,

Antoniuk

et al. 2024

Brain Sciences

View full text Add to dashboard Cite

Background and Objectives: Impulse control disorders (ICDs) are characterized by potentially harmful actions resulting from disturbances in the self-control of emotions and behavior. ICDs include disorders such as gambling, hypersexuality, binge eating, and compulsive buying. ICDs are known non-motor symptoms in Parkinson’s disease (PD) and are associated primarily with the use of dopaminergic treatment (DRT) and especially dopamine agonists (DA). However, in atypical parkinsonism (APS), such as progressive supranuclear palsy (PSP) or multiple system atrophy (MSA), there are only single case reports of ICDs without attempts to determine the risk factors for their occurrence. Moreover, numerous reports in the literature indicate increased impulsivity in PSP. Our study aimed to determine the frequency of individual ICDs in APS compared to PD and identify potential factors for developing ICDs in APS. Materials and Methods: Our prospective study included 185 patients with PD and 35 with APS (27 patients with PSP and 9 with MSA) hospitalized between 2020 and 2023 at the Neurological Department of University Central Hospital in Katowice. Each patient was examined using the Questionnaire for Impulsive–Compulsive Disorders in Parkinson’s Disease (QUIP) to assess ICDs. Additionally, other scales were used to assess the advancement of the disease, the severity of depression, and cognitive impairment. Information on age, gender, age of onset, disease duration, and treatment used were collected from medical records and patient interviews. Results: ICDs were detected in 23.39% of patients with PD (including binge eating in 11.54%, compulsive buying in 10.44%, hypersexuality in 8.79%, and pathological gambling in 4.40%), in one patient with MSA (hypersexuality and pathological gambling), and in 18.52% of patients with PSP (binge eating in 3.70%, compulsive buying in 7.41%, and hypersexuality in 11.11%). We found no differences in the frequency of ICDs between individual diseases (p = 0.4696). We confirmed that the use of higher doses of DA and L-dopa in patients with PD, as well as a longer disease duration and the presence of motor complications, were associated with a higher incidence of ICDs. However, we did not find any treatment effect on the incidence of ICDs in APS. Conclusions: ICDs are common and occur with a similar frequency in PD and APS. Well-described risk factors for ICDs in PD, such as the use of DRT or longer disease duration, are not fully reflected in the risk factors for ICDs in APS. This applies especially to PSP, which, unlike PD and MSA, is a tauopathy in which, in addition to the use of DRT, other mechanisms related to the disease, such as disorders in neuronal loops and neurotransmitter deficits, may influence the development of ICDs. Further prospective multicenter studies recruiting larger groups of patients are needed to fully determine the risk factors and mechanisms of ICD development in APS.

show abstract

Section: Discussionmentioning

confidence: 99%

Impulse Control Disorders in Parkinson’s Disease and Atypical Parkinsonian Syndromes—Is There a Difference?

Toś,

Grażyńska,

Antoniuk

et al. 2024

Brain Sciences

View full text Add to dashboard Cite

show abstract

“…It is hypothesised that in AD sleep may be affected by abnormalities in orexin regulations, which may be linked with tau and beta-amyloid secretion, accumulation and clearance [31]. Orexin is related with abnormalities in parkinsonisms, although it is not known whether the factor is one of the causes of, or rather a consequence of, the pathological pathways observed in the diseases [32,33]. In diseases affected by Lewy bodies such as PD or DLB, the pathology selectively affects the regions of the hypothalamus, among which can be mentioned orexin/ /hypocretin neurons, tuberomammillary nucleus and lateral tuberal nucleus [34,35].…”

Section: Orexin In Parkinsonismsmentioning

confidence: 99%

Role of orexin in pathogenesis of neurodegenerative parkinsonisms

Alster

Madetko

Otto-Ślusarczyk

et al. 2023

Neurol Neurochir Pol.

View full text Add to dashboard Cite

Introduction.The pathogenesis of parkinsonisms is not fully understood. Among possible factors which may influence the course of neurodegenerative diseases, endocrine abnormalities may be interpreted as having been underevaluated. State of the art.Growing interest is associated with the role of neuropeptides such as orexin. Orexin is a neuropeptide produced by orexigenic neurons in the lateral parts of the hypothalamus and is linked with excitement, wakefulness and appetite. An extended analysis of this neuropeptide might answer whether changes in the metabolism of orexin is more likely to be a cause or a consequence of neurodegeneration. Clinical significance.Orexin is a neuropeptide produced by orexigenic neurons in the lateral parts of the hypothalamus and is linked with excitement, wakefulness and appetite. The aim of this study was to discuss the role of this factor and its abnormalities in the pathogenesis and course of parkinsonian syndrome. Future directions.Understanding the role of orexin in these diseases may be interpreted as an important feature in evolving therapeutical methods. Further evaluation based on larger groups of patients is required.

show abstract

“…These findings include neurodegenerative biomarker research, longitudinal cohort outcome investigations, and pathological confirmation from both autopsy series and demonstration of extranigral α-synuclein pathology in living patients with RBD [ 16 ]. Furthermore, a recent review has highlighted that RBD, which has been primarily described in synucleinopathies, has also been found to be present in other atypical parkinsonisms such as progressive supranuclear palsy syndrome (PSPS) and corticobasal syndrome (CBS) [ 18 ]. Among RBD patients, it was observed that 74% of subjects met Movement Disorders Society criteria for a diagnosis of prodromal PD [ 19 ].…”

Section: Introductionmentioning

confidence: 99%

Olfactory Impairment Is the Main Predictor of Higher Scores at REM Sleep Behavior Disorder (RBD) Screening Questionnaire in Parkinson’s Disease Patients

et al. 2023

View full text Add to dashboard Cite

Introduction: Olfactory impairment and REM sleep behavior disorder (RBD) are common non-motor symptoms in Parkinson’s disease (PD) patients, often preceding the onset of the specific motor symptoms and, thus, crucial for strategies directed to anticipate PD diagnosis. In this context, the specific interaction between olfactory impairment and RBD has not been clearly defined. Objective: The aim of this study was to determine the possible role of olfactory impairment and other clinical characteristics as possible predictors of higher scores at RBD screening questionnaire (RBDSQ) in a large population of PD patients. Methods: In this study, 590 PD patients were included from the Parkinson’s Progression Markers Initiative. Demographic and clinical features were registered. All participants completed motor and non-motor evaluations at the baseline visit. For motor assessments, the disease severity was evaluated by the Movement Disorder Society-Unified Parkinson’s Disease Rating Scale (MDS-UPDRS) pars III. Regarding non-motor symptoms assessment, Montreal Cognitive Assessments (MoCA), University of Pennsylvania Smell Identification Test (UPSIT) and RBD screening questionnaire (RBDSQ) were registered. Results: Among 590 PD patients included in this study, 111 patients with possible RBD were found (18.8%). RBD was less frequent in female PD patients (p ≤ 0.011). Among patients with or without possible RBD diagnosis, statistically significant differences in MDS-UPDRS III (23.3 ± 11.4 vs. 19.7 ± 9.1, respectively, p ≤ 0.002) and in UPSIT score (19.7 ± 8.3 vs. 22.6 ± 8.0, respectively, p ≤ 0.001) were found. Moreover, significant correlations between RBDSQ versus UPDRS III score and versus UPSIT score were observed. Multivariate linear regression analysis showed that UPSIT was the most significant predictor of higher scores at RBDSQ, while the other significant predictors were UPDRS III and age. Conclusions: The severity of olfactory impairment appears tightly correlated to RBD symptoms, highlighting the role of these biomarkers for PD patients. Additionally, according to this large study, our data confirmed that RBD in PD patients exhibits peculiar gender differences.

show abstract

Sleep disturbances in progressive supranuclear palsy syndrome (PSPS) and corticobasal syndrome (CBS)

Cited by 6 publications

References 61 publications

Impulse Control Disorders in Parkinson’s Disease and Atypical Parkinsonian Syndromes—Is There a Difference?

Impulse Control Disorders in Parkinson’s Disease and Atypical Parkinsonian Syndromes—Is There a Difference?

Role of orexin in pathogenesis of neurodegenerative parkinsonisms

Olfactory Impairment Is the Main Predictor of Higher Scores at REM Sleep Behavior Disorder (RBD) Screening Questionnaire in Parkinson’s Disease Patients

Contact Info

Product

Resources

About